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Background: The Nile PAX® dedicated drug-eluting stent (Minvasys SAS, France) is a novel technology designed for bifurcation lesions treatment 
that incorporates the: 1. a cobalt-chromium alloy designed to optimize scaffold of the bifurcation carina with maintenance of side branch (SB) 
access without need for rewiring (Nile CroCo® platform, Minvasys SAS, France); 2. a non-polymeric coating (PAX) technology; and 3. a potent 
antiproliferative agent (paclitaxel). 
Methods: From Dec/08 to Mar/09, a total of 102 pts with single bifurcation lesion were prospectively enrolled in this non-randomized, multicenter 
(10 sites in Europe/South America) study. Lesion criteria were vessel size 2.5-3.5mm in the parent vessel (PV) and 2.0-3.0mm in the SB, and lesion 
length <14mm in the PV. Clinical follow-up (FU) was scheduled at 1, 3, 6, 9 and 12 months, and yearly up to 5 years. Angiographic FU was scheduled 
at 9 months (primary endpoint). All clinical events were adjudicated by an independent clinical events committee. 
Results: Mean age was 63 years, 29% had diabetes, 16 previous MI, and 40% previous intervention. The LAD/Dg was the most prevalent location 
(75%), and 60% had significant involvement of both branches. In the procedure, PV was predilated in 97%; the study stent was successfully 
attempted and implanted in 99%. Overall, 25% of SB received an additional stent; and 94% had final kissing-balloon inflation. By QCA, baseline 
mean lesion length, vessel diameter and % diameter stenosis were: 10.9mm, 2.99mm and 72% in the PV, and 4.1mm, 2.28mm, and 38% in the 
SB, respectively; angiographic success (residual stenosis <50%, final TIMI 3 flow, and absence of dissection) was achieved in 98%. There was only 1 
MACE during hospitalization, which was adjudicated as a non-Q myocardial infarction during hospitalization, and no additional adverse events were 
reported up to 30 days FU. 
Conclusions: The novel Nile PAX dedicated bifurcation polymer-free technology demonstrated excellent performance in the treatment of complex 
bifurcation lesions, including high procedural success and no events from discharge to 30 days FU. Complete 6 months FU will be presented at the 
meeting.
